NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR

• US 20110282029A1
• Filed: 12/10/2010
• Published: 11/17/2011
• Est. Priority Date: 11/11/2004
• Status: Abandoned Application

• Current Assignee: Affymax Incorporated
• Original Assignee: Affymax Incorporated
• Inventors: Lalonde, Guy, Frederick, Brian T., Balu, Palani, Tumelty, David, Schatz, Peter J., Chakrabarti, Anjan, Wrighton, Nicholas C., Dong, Yaohua S., Bhandari, Ashok, Zemede, Genet, Dower, William J., Holmes, Christopher P., Yin, Qun
• Application Number:
  US12/965,167
• Publication Number:
  US 20110282029A1
• Time in Patent Office: Days
• US Class Current: 530/323
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C07K 14/505 Erythropoietin [EPO]

Abstract

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Claims

1. A peptide comprising an amino acid sequences selected from SEQ ID NOS:

1-734 according to FIGS. 1A to 1TT.

2-58. -58. (canceled)